Cargando…

Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study

BACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatiti...

Descripción completa

Detalles Bibliográficos
Autores principales: Kieran, Jennifer Ann, Norris, Suzanne, O’Leary, Aisling, Walsh, Cathal, Merriman, Raphael, Houlihan, D., McCormick, P. Aiden, McKiernan, Susan, Bergin, Colm, Barry, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624167/
https://www.ncbi.nlm.nih.gov/pubmed/26503519
http://dx.doi.org/10.1186/s12879-015-1208-1
_version_ 1782397787469512704
author Kieran, Jennifer Ann
Norris, Suzanne
O’Leary, Aisling
Walsh, Cathal
Merriman, Raphael
Houlihan, D.
McCormick, P. Aiden
McKiernan, Susan
Bergin, Colm
Barry, Michael
author_facet Kieran, Jennifer Ann
Norris, Suzanne
O’Leary, Aisling
Walsh, Cathal
Merriman, Raphael
Houlihan, D.
McCormick, P. Aiden
McKiernan, Susan
Bergin, Colm
Barry, Michael
author_sort Kieran, Jennifer Ann
collection PubMed
description BACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis related group costs. METHODS: The staff utilisation costs associated with a Hepatitis C ambulatory visit were measured and combined with the costs of investigations to establish a mean cost per consultation. An annualised estimate of cost was produced by multiplying this by the number of consultations accessed, stratified by degree of liver impairment. Inpatient costs were established by identifying the number of inpatient episodes and multiplying by Irish diagnosis related group costs. Non-parametric bootstrapping was performed to derive mean and 95%CI values. RESULTS: Two hundred and twenty-five patients were identified. The cost of an outpatient medical review was €136 (€3.60 SD). The cost of a Hepatitis C nursing review was €128 (€7.30 SD). The annual mean costs of care were as follows (95%CI): Mild €398 (€336, €482), Moderate €417(€335, €503), Compensated cirrhosis €1790 (€990, €3164), Decompensated cirrhosis €8302 (€3945, €14,637), Transplantation Year 1 €137,176 (€136,024, €138,306), Transplantation after Year 1 €5337 (€4942, €5799), Hepatocellular carcinoma €21,992 (€15,222, €29,467), Sustained virological response €44 (€16, €73). CONCLUSIONS: The direct medical cost associated with Hepatitis C care in Ireland is substantial and increases exponentially with progression of liver disease. The follow-up costs of patients with a sustained virological response in this cohort were low in comparison to patients with chronic infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1208-1) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4624167
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-46241672015-10-29 Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study Kieran, Jennifer Ann Norris, Suzanne O’Leary, Aisling Walsh, Cathal Merriman, Raphael Houlihan, D. McCormick, P. Aiden McKiernan, Susan Bergin, Colm Barry, Michael BMC Infect Dis Research Article BACKGROUND: Recent advances in Hepatitis C therapeutics offer the possibility of cure but will be expensive. The cost of treatment may be partially offset by the avoidance of advanced liver disease. We performed a micro-costing study of the ambulatory healthcare utilisation of patients with Hepatitis C supplemented with inpatient diagnosis related group costs. METHODS: The staff utilisation costs associated with a Hepatitis C ambulatory visit were measured and combined with the costs of investigations to establish a mean cost per consultation. An annualised estimate of cost was produced by multiplying this by the number of consultations accessed, stratified by degree of liver impairment. Inpatient costs were established by identifying the number of inpatient episodes and multiplying by Irish diagnosis related group costs. Non-parametric bootstrapping was performed to derive mean and 95%CI values. RESULTS: Two hundred and twenty-five patients were identified. The cost of an outpatient medical review was €136 (€3.60 SD). The cost of a Hepatitis C nursing review was €128 (€7.30 SD). The annual mean costs of care were as follows (95%CI): Mild €398 (€336, €482), Moderate €417(€335, €503), Compensated cirrhosis €1790 (€990, €3164), Decompensated cirrhosis €8302 (€3945, €14,637), Transplantation Year 1 €137,176 (€136,024, €138,306), Transplantation after Year 1 €5337 (€4942, €5799), Hepatocellular carcinoma €21,992 (€15,222, €29,467), Sustained virological response €44 (€16, €73). CONCLUSIONS: The direct medical cost associated with Hepatitis C care in Ireland is substantial and increases exponentially with progression of liver disease. The follow-up costs of patients with a sustained virological response in this cohort were low in comparison to patients with chronic infection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12879-015-1208-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-10-26 /pmc/articles/PMC4624167/ /pubmed/26503519 http://dx.doi.org/10.1186/s12879-015-1208-1 Text en © Kieran et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Kieran, Jennifer Ann
Norris, Suzanne
O’Leary, Aisling
Walsh, Cathal
Merriman, Raphael
Houlihan, D.
McCormick, P. Aiden
McKiernan, Susan
Bergin, Colm
Barry, Michael
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
title Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
title_full Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
title_fullStr Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
title_full_unstemmed Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
title_short Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study
title_sort hepatitis c in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis c; a cross-sectional study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4624167/
https://www.ncbi.nlm.nih.gov/pubmed/26503519
http://dx.doi.org/10.1186/s12879-015-1208-1
work_keys_str_mv AT kieranjenniferann hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT norrissuzanne hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT olearyaisling hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT walshcathal hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT merrimanraphael hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT houlihand hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT mccormickpaiden hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT mckiernansusan hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT bergincolm hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy
AT barrymichael hepatitiscintheeraofdirectactingantiviralsrealworldcostsofuntreatedchronichepatitiscacrosssectionalstudy